NF1 mutation	Glioblastoma	NF1 mutation	Glioblastoma	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
NF1 mutation	CNS Tumor	NF1 mutation	CNS Tumor	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
NF1 mutation	Glioma	NF1 mutation	Glioma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
NF1 mutation	Melanoma	NF1 mutation	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
NF1 mutation	Thyroid Gland Anaplastic Carcinoma	NF1 mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
NF1 mutation	Colorectal Cancer	NF1 mutation	Colorectal Cancer	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3
NF1 mutation	Multiple Myeloma	NF1 mutation	Multiple Myeloma	MEK inhibitor Sensitive: C3 – Early Trials MEK inhibitor Sensitive : C3	MEK inhibitor Sensitive: C3 – Early Trials MEK inhibitor Sensitive : C3
NF1 mutation	Solid Tumor	NF1 mutation	Solid Tumor	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
NF1 mutation	Melanoma	NF1 mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NF1 mutation	Melanoma	NF1 mutation	Melanoma	PD1 inhibitor + MEK inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + MEK inhibitor Sensitive : C3	PD1 inhibitor + MEK inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + MEK inhibitor Sensitive : C3
NF1 mutation	Soft Tissue Sarcoma	NF1 mutation	Soft Tissue Sarcoma	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3
NF1 mutation	Glioblastoma	NF1 mutation	Glioblastoma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3

NF1 mutation

Associations